LONDON -(Dow Jones)- The U.K.'s health-care costs regulator said Wednesday it isn't recommending Bristol-Myers Squibb Co.'s (BMY) drug Orencia, also known as abatacept, for use in the state-funded National Health Service for treating adults with moderate to severe active rheumatoid arthritis who haven't responded to conventional non-biological anti-rheumatic drugs, largely due to cost considerations.
